Clinical trial
Phase I Study of Nimotuzumab in Solid Tumours
NCT00369252 · YM BioSciences, Industry · Completed
Key facts
| NCT number | NCT00369252 |
|---|---|
| Title | Phase I Study of Nimotuzumab in Solid Tumours |
| Official title | A Phase I Study of TheraCIM-hR3 (YMB1000) in Patients With Solid Tumours |
| Lead sponsor | YM BioSciences, Industry |
| Collaborators | CIMYM BioSciences |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Advanced and/or Metastatic Solid Tumours |
| Intervention type | Drug |
| Interventions | Nimotuzumab (TheraCIM h-R3) |
| Enrollment | 18 |
| Start date | Jun 1, 2005 |
| First posted | Aug 29, 2006 |
| Last update posted | Feb 28, 2007 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: